Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma: Two case reports.
Angiosarcoma
Breast cancer
Case report
Neoadjuvant chemotherapy
Radiation-induced angiosarcoma
Sarcoma
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
12
2019
revised:
10
02
2020
accepted:
16
02
2020
pubmed:
3
3
2020
medline:
3
3
2020
entrez:
3
3
2020
Statut:
ppublish
Résumé
Angiosarcoma is a rare soft tissue malignancy of endothelial cells, generally associated with a poor prognosis. Due to its rarity, randomized trials are difficult to conduct and a consensus on the treatment of angiosarcoma has not been reached. The role, efficacy, and timing of chemotherapy in AS treatment remain uncertain, and as stated, no large-scale trials have been able to establish definitive recommendations. Here we describe the successful use of chemotherapy followed by radiation for a case of lower extremity angiosarcoma, and a case of breast angiosarcoma treated with neoadjuvant chemotherapy followed by surgical resection. Systemic therapy consisted of weekly doxorubicin, paclitaxel, and cisplatin. This regimen resulted in a full clinical remission in the first patient and a pathologic complete response in the second. These cases suggest that the use of the doxorubicin, cisplatin and paclitaxel combination could be an effective alternative to radical surgical excision in extremity sarcomas, and an effective adjuvant treatment to mastectomy in cutaneous radiation-associated angiosarcoma of the breast due to their independent efficacy against angiosarcoma. A randomized trial utilizing neoadjuvant combined doxorubicin, paclitaxel and cisplatin followed by either surgery or radiation, with endpoints assessing pathologic and overall response as well as progression free survival is warranted based on these cases. The role of neoadjuvant chemotherapy in the treatment of angiosarcoma should be reconsidered considering its ability to provide important prognostic information and improve the likelihood of curative surgery.
Identifiants
pubmed: 32120283
pii: S2210-2612(20)30110-3
doi: 10.1016/j.ijscr.2020.02.036
pmc: PMC7052479
pii:
doi:
Types de publication
Case Reports
Langues
eng
Pagination
83-87Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Pediatr Blood Cancer. 2011 Dec 1;57(6):943-9
pubmed: 21793180
J Clin Oncol. 2009 Jul 1;27(19):3133-40
pubmed: 19451436
Cancer. 2015 Jan 15;121(2):276-85
pubmed: 25209242
Eur J Cancer. 2014 Jul;50(10):1779-1788
pubmed: 24731859
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
pubmed: 11481490
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
J Clin Oncol. 1993 Jul;11(7):1269-75
pubmed: 8315424
Cancer. 2005 Jul 15;104(2):361-6
pubmed: 15948172
J Clin Oncol. 2008 Nov 10;26(32):5269-74
pubmed: 18809609
Am J Clin Oncol. 2014 Oct;37(5):473-9
pubmed: 23428947
Ann Surg Oncol. 2012 Nov;19(12):3801-8
pubmed: 22890593
J Am Acad Dermatol. 2006 Mar;54(3):499-504
pubmed: 16488303
Eur J Cancer. 2014 Dec;50(18):3178-86
pubmed: 25459395
Lancet Oncol. 2006 Jan;7(1):92-3
pubmed: 16389189
J Clin Oncol. 2003 Feb 15;21(4):588-92
pubmed: 12586793
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279
Oncologist. 2012;17(3):405-18
pubmed: 22334455
Cancer. 1948 May;1(1):64-81
pubmed: 18867440
PLoS One. 2017 Sep 27;12(9):e0185654
pubmed: 28953936
BMC Cancer. 2017 Apr 27;17(1):295
pubmed: 28449661
Acta Oncol. 2008;47(8):1475-82
pubmed: 18607853
Head Neck. 2008 May;30(5):639-46
pubmed: 18213722
J Clin Oncol. 2015 Sep 1;33(25):2797-802
pubmed: 26215950
Ann Surg. 2017 Apr;265(4):814-820
pubmed: 28267696
N Engl J Med. 1995 Apr 13;332(15):1004-14
pubmed: 7885406
Lancet Oncol. 2010 Oct;11(10):983-91
pubmed: 20537949